miR-486-5p inhibits cell proliferation and invasion through repressing GAB2 in non-small cell lung cancer

Yu,Sunfeng; Geng,Shuang; Hu,Yi

doi:10.3892/ol.2018.9053

miR-486-5p inhibits cell proliferation and invasion through repressing GAB2 in non-small cell lung cancer

Authors:
- Sunfeng Yu
- Shuang Geng
- Yi Hu
View Affiliations

Affiliations: Department of Respiratory Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China
Published online on: June 29, 2018 https://doi.org/10.3892/ol.2018.9053
Pages: 3525-3530

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have reported that cell metastasis is the main reason for the high mortality of non-small cell lung cancer (NSCLC). Many miRNAs have been identified to be involved in the development of NSCLC. In this study, we explored the effect of miR-486-5p and GAB2 on cell proliferation and invasion in NSCLC. First, miR-486-5p and GAB2 expression levels were detected in NSCLC through quantitative RT-qPCR, and downregulation of miR-486-5p and upregulation of GAB2 were both identified in NSCLC. Then MTT and Transwell analysis were performed to confirm the functions of miR-486-5p and GAB2 for cell proliferation and invasion in NSCLC. Moreover, miR-486-5p overexpression was found to inhibit proliferation and invasion by suppressing GAB2 in NSCLC cells. Besides, miR-486-5p overexpression lessened GAB2 expression level in NSCLC, while miR-486-5p knockout enhanced GAB2 expression level. Additionally, miR-486-5p was identified to directly target GAB2 through dual luciferase reporter assay. The silence of GAB2 was found to inhibit proliferation and invasion of NSCLC cells. Collectively, miR-486-5p contributed to inhibiting proliferation and invasion of NSCLC cells through regulating GAB2, and miR-486-5p/GAB2 axis may provide a breakthrough for diagnosing NSCLC.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Fassina A, Cappellesso R and Fassan M: Classification of non-small cell lung carcinoma in transthoracic needle specimens using microRNA expression profiling. Chest. 140:1305–1311. 2011. View Article : Google Scholar : PubMed/NCBI
4	Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
5	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
6	Oom AL, Humphries BA and Yang C: MicroRNAs: Novel players in cancer diagnosis and therapies. BioMed Res Int. 2014:9594612014. View Article : Google Scholar : PubMed/NCBI
7	Li J, Wang Y, Luo J, Fu Z, Ying J, Yu Y and Yu W: miR-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells. FEBS Lett. 586:3761–3765. 2012. View Article : Google Scholar : PubMed/NCBI
8	Wang P, Lv HY, Zhou DM and Zhang EN: miR-204 suppresses non-small-cell lung carcinoma (NSCLC) invasion and migration by targeting JAK2. Genet Mol Res. 15:gmr64152016.
9	Zhou YL, Xu YJ and Qiao CW: MiR-34c-3p suppresses the proliferation and invasion of non-small cell lung cancer (NSCLC) by inhibiting PAC1/MAPK pathway. Int J Clin Exp Pathol. 8:6312–6322. 2015.PubMed/NCBI
10	Xiao P, Liu W and Zhou H: miR-200b inhibits migration and invasion in non-small cell lung cancer cells via targeting FSCN1. Mol Med Rep. 14:1835–1840. 2016. View Article : Google Scholar : PubMed/NCBI
11	Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K and Yang GH: MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 411:846–852. 2010. View Article : Google Scholar : PubMed/NCBI
12	Duan B, Guo T, Sun H, Cai R, Rui Q and Xi Z: miR-205 as a biological marker in non-small cell lung cancer. Biomed Pharmacother. 91:823–830. 2017. View Article : Google Scholar : PubMed/NCBI
13	Ye L, Wang H and Liu B: miR-211 promotes non-small cell lung cancer proliferation by targeting SRCIN1. Tumour Biol. 37:1151–1157. 2016. View Article : Google Scholar : PubMed/NCBI
14	Li T, Ding ZL, Zheng YL and Wang W: MiR-484 promotes non-small-cell lung cancer (NSCLC) progression through inhibiting Apaf-1 associated with the suppression of apoptosis. Biomed Pharmacother. 96:153–164. 2017. View Article : Google Scholar : PubMed/NCBI
15	Sun H, Cui C, Xiao F, Wang H, Xu J, Shi X, Yang Y, Zhang Q, Zheng X, Yang X, et al: miR-486 regulates metastasis and chemosensitivity in hepatocellular carcinoma by targeting CLDN10 and CITRON. Hepatol Res. 45:1312–1322. 2015. View Article : Google Scholar : PubMed/NCBI
16	Tan K, Huang G and Fang Q: MiR-486-5p prevents migration, invasion and EMT by regulating smad2 in breast cancer. Int J Clin Exp Med. 10:8942–8949. 2017.
17	Alexander MS, Casar JC, Motohashi N, Vieira NM, Eisenberg I, Marshall JL, Gasperini MJ, Lek A, Myers JA, Estrella EA, et al: MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms. J Clin Invest. 124:2651–2667. 2014. View Article : Google Scholar : PubMed/NCBI
18	Xu J, Li R, Workeneh B, Dong Y, Wang X and Hu Z: Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486. Kidney Int. 82:401–411. 2012. View Article : Google Scholar : PubMed/NCBI
19	Li Y, Ma C, Qian M, Wen Z, Jing H and Qian D: Downregulation of NOB1 suppresses the proliferation and tumor growth of non-small cell lung cancer in vitro and in vivo. Oncol Rep. 31:1271–1276. 2014. View Article : Google Scholar : PubMed/NCBI
20	Wang Y, Li Y, Wu B, Shi C and Li C: MicroRNA-661 promotes non-small cell lung cancer progression by directly targeting RUNX3. Mol Med Rep. 16:2113–2120. 2017. View Article : Google Scholar : PubMed/NCBI
21	Ke Y, Zhao W, Xiong J and Cao R: MiR-149 inhibits non-small-cell lung cancer cells emt by targeting FOXM1. Biochem Res Int. 2013:5067312013. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Li W, Wang Y, Zhang Q, Tang L, Liu X, Dai Y, Xiao L, Huang S, Chen L, Guo Z, et al: Correction: MicroRNA-486 as a biomarker for early diagnosis and recurrence of non-small cell lung cancer. PLoS One. 11:e01485892016. View Article : Google Scholar : PubMed/NCBI
24	Shao Y, Shen YQ, Li YL, Liang C, Zhang BJ, Lu SD, He YY, Wang P, Sun QL, Jin YX, et al: Direct repression of the oncogene CDK4 by the tumor suppressor miR-486-5p in non-small cell lung cancer. Oncotarget. 7:34011–34021. 2016. View Article : Google Scholar : PubMed/NCBI
25	Zhang X, Zhang T, Yang K, Zhang M and Wang K: miR-486-5p suppresses prostate cancer metastasis by targeting Snail and regulating epithelial-mesenchymal transition. OncoTargets Ther. 9:6909–6914. 2016. View Article : Google Scholar
26	Yi Y, Lu X, Chen J, Jiao C, Zhong J, Song Z, Yu X and Lin B: Downregulated miR-486-5p acts as a tumor suppressor in esophageal squamous cell carcinoma. Exp Ther Med. 12:3411–3416. 2016. View Article : Google Scholar : PubMed/NCBI
27	Wang J, Tian X, Han R, Zhang X, Wang X, Shen H, Xue L, Liu Y, Yan X, Shen J, et al: Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene. 33:1181–1189. 2014. View Article : Google Scholar : PubMed/NCBI
28	Ding CB, Yu WN, Feng JH and Luo JM: Structure and function of Gab2 and its role in cancer (Review). Mol Med Rep. 12:4007–4014. 2015. View Article : Google Scholar : PubMed/NCBI
29	Tian LQ, Liu EQ, Zhu XD, Wang XG, Li J and Xu GM: MicroRNA-197 inhibits cell proliferation by targeting GAB2 in glioblastoma. Mol Med Rep. 13:4279–4288. 2016. View Article : Google Scholar : PubMed/NCBI
30	Lee SH, Jeong EG, Nam SW, Lee JY, Yoo NJ and Lee SH: Increased expression of Gab2, a scaffolding adaptor of the tyrosine kinase signalling, in gastric carcinomas. Pathology. 39:326–329. 2007. View Article : Google Scholar : PubMed/NCBI
31	Gu DH, Mao JH, Pan XD, Zhu H, Chen X, Zheng B and Shan Y: microRNA-302c-3p inhibits renal cell carcinoma cell proliferation by targeting Grb2-associated binding 2 (Gab2). Oncotarget. 8:26334–26343. 2017.PubMed/NCBI
32	Xu XL, Wang X, Chen ZL, Jin M, Yang W, Zhao GF and Li JW: Overexpression of Grb2-associated binder 2 in human lung cancer. Int J Biol Sci. 7:496–504. 2011. View Article : Google Scholar : PubMed/NCBI
33	Xu LJ, Wang YC, Lan HW, Li J and Xia T: Grb2-associated binder-2 gene promotes migration of non-small cell lung cancer cells via Akt signaling pathway. Am J Transl Res. 8:1208–1217. 2016.PubMed/NCBI